Is Agios Pharm (AGIO) overvalued? · rev $36.5M
Agios Pharm (AGIO) is a biotechnology company listed on US.
This page asks whether Agios Pharm (AGIO) looks expensive on cached numbers — not a short thesis.
Latest reported AGIO revenue for 2024-12-31 was $36.5M. Net income was $673.7M. Revenue was up 36.1% from 2023-12-31 to 2024-12-31. AGIO currently screens at market cap $1.68B.
AGIO currently screens at market cap $1.68B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next AGIO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the AGIO stock page for the full model, not this heading.
Not investment advice.